Cargando…

Post-marketing Study of Linagliptin: A Pilot Study

INTRODUCTION: Linagliptin is a high-cost oral antidiabetic that has been widely used, and studies on its effectiveness and safety for the treatment of type 2 diabetes mellitus (DM2) in the real world is rare and necessary. OBJECTIVE: To analyze the values of glycated hemoglobin (HbA1c) and adverse e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomes, Gabrielle Kéfrem Alves, Pereira, Mariana Linhares, Sanches, Cristina, Baldoni, André Oliveira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543281/ https://www.ncbi.nlm.nih.gov/pubmed/31178735 http://dx.doi.org/10.3389/fphar.2019.00576

Ejemplares similares

Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
por: Li, Yong, et al.
Publicado: (2020)

Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
por: Fazeli Farsani, Soulmaz, et al.
Publicado: (2019)

Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis
por: Li, Yi, et al.
Publicado: (2020)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
por: Lee, Yueh-Ting, et al.
Publicado: (2021)

Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study
por: Yamamoto, Fumiko, et al.
Publicado: (2020)

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin
por: Miyawaki, Yoshia, et al.
Publicado: (2018)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
por: Liu, Wensheng, et al.
Publicado: (2023)

Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study
por: Yamamoto, Fumiko, et al.
Publicado: (2019)

Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study
por: Kang, Jieun, et al.
Publicado: (2023)

Linagliptin and secoisolariciresinol diglucoside attenuate hyperlipidemia and cardiac hypertrophy induced by a high-methionine diet in rats via suppression of hyperhomocysteinemia-induced endoplasmic reticulum stress
por: Jalal, Israa A., et al.
Publicado: (2023)

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance
por: Wakabayashi, Tomohito, et al.
Publicado: (2022)

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

Post-Marketing Health Technology Monitoring. The Analysis of an Experience from a Clinical Perspective
por: Ibargoyen-Roteta, Nora, et al.
Publicado: (2011)

The clinical application of linagliptin in Asians
por: Cao, Chu-qing, et al.
Publicado: (2015)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate
por: Park, Jeewon, et al.
Publicado: (2020)

Kidney Injury Following Ibuprofen and Acetaminophen: A Real-World Analysis of Post-Marketing Surveillance Data
por: Shao, Qi-hui, et al.
Publicado: (2021)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data
por: Ni, Ming, et al.
Publicado: (2022)

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
por: Guedes, Erika Paniago, et al.
Publicado: (2013)

Tissue concentration of vascular endothelial growth factor is not related to the depth of trophoblastic invasion in ampullary pregnancies—A pilot study
por: Teshima, Décio Roberto Kamio, et al.
Publicado: (2022)

Biological Safety Studies and Simultaneous Determination of Linagliptin and Synthetic Impurities by LC-PDA
por: Heleno Ferreira, Raquel Balestri, et al.
Publicado: (2019)

Linagliptin-Associated Alopecia and Bullous Pemphigoid
por: Someili, Ali, et al.
Publicado: (2019)

Incorrect description of mode of excretion of linagliptin
por: Woerle, Hans-Juergen, et al.
Publicado: (2010)

Acute Kidney Injury Associated with Linagliptin
por: Nandikanti, Deepak K., et al.
Publicado: (2016)

Relationship Between Cardiovascular Disease Pathology and Fatal Opioid and Other Sedative Overdose: A Post-Mortem Investigation and Pilot Study
por: Arab, Abdulmalik Zuhair, et al.
Publicado: (2021)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
por: Jadhav, Sushant B., et al.
Publicado: (2016)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
por: Jiang, Tingting, et al.
Publicado: (2022)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
por: Car, Elif, et al.
Publicado: (2023)

Clinical utility and tolerability of linagliptin in diabetic patients
por: Maxwell, Lauralee Gordon, et al.
Publicado: (2013)

Atypical Bullous Pemphigoid After Linagliptin Intake
por: Dbouk, Samer, et al.
Publicado: (2021)

Adoption of Pharmacogenomic Testing: A Marketing Perspective
por: Koufaki, Margarita-Ioanna, et al.
Publicado: (2021)

A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus
por: Gross, Jorge Luiz, et al.
Publicado: (2013)

Editorial: New Horizons in Health-Promoting: From Methods to Implementation Science
por: Barberato-Filho, Silvio, et al.
Publicado: (2022)

Recipient rs1045642 Polymorphism Is Associated With Office Blood Pressure at 1-Year Post Kidney Transplantation: A Single Center Pharmacogenetic Cohort Pilot Study
por: Bouatou, Yassine, et al.
Publicado: (2018)

CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial
por: Nath, Baishali, et al.
Publicado: (2020)

Uncovering Modern Clinical Applications of Fuzi and Fuzi-Based Formulas: A Nationwide Descriptive Study With Market Basket Analysis
por: Tai, Chi-Jung, et al.
Publicado: (2021)

Recent Advances in Pharmaceutical Cocrystals: From Bench to Market
por: Kumar Bandaru, Ravi, et al.
Publicado: (2021)

An international comparative analysis and roadmap to sustainable biosimilar markets
por: Alnaqbi, Khalid A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4h2gi8qje68qtkbbeib7f8l9lu